This is a very controversial field, not just for CHEK2 but many other genes. The more testing we do, the more variants are discovered and it is not always easy to determine which ones are actually associated with cancer incidence, which ones have a cancer risk that would change management or which ones are innocent bystanders. As a result, NCCN is continually reviewing the evidence and revising the guidelines as appropriate.
Reply to the Letter to the Editor From Ivanov et al
Author:
Mary B. Daly
MD, PhD
Mary B. Daly
Chair, NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic; Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania
Search for other papers by Mary B. Daly in
Current site
Google Scholar
PubMed
Search for other papers by Mary B. Daly in
Current site
Google Scholar
PubMed
© 2019-2024 National Comprehensive Cancer Network